文献速递瓣膜外科

原生二尖瓣感染性心内膜炎的结构化手术策略:修复是否优于置换

A structured approach to native mitral valve infective endocarditis: Is repair better than replacement?
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该单中心回顾性研究纳入2000年至2017年149例原生二尖瓣感染性心内膜炎手术患者,其中97例(66%)行瓣膜修复、52例(34%)行瓣膜置换,采用早期手术、彻底切除感染组织、宽松使用人工材料及补片修复技术的结构化策略。院内死亡率15.4%(修复14例 vs 置换9例,P=0.642),术后1年内置换不劣于修复(HR 1.134,95%CI 0.504-2.540,P=0.76),但1年后置换与生存率降低相关(HR 2.534,95%CI 1.002-6.406,P=0.049)。

要点

  • 结构化策略可使约三分之二原生二尖瓣感染性心内膜炎患者成功行瓣膜修复。
  • 术后1年内瓣膜置换不劣于修复,但1年后置换与生存率降低独立相关。
  • 复发感染性心内膜炎与二尖瓣再干预率在修复与置换间无差异。

核心结论

  • 原生二尖瓣活动性感染性心内膜炎仍是复杂疾病,早期和晚期并发症及死亡率显著。
  • 结构化策略可实现约三分之二患者的瓣膜修复,但修复的生存获益主要体现在术后1年以后。

研究设计与样本

  • 单中心回顾性队列研究,纳入2000年1月至2017年1月共149例因原生二尖瓣感染性心内膜炎接受手术的患者。
  • 97例(66%)行瓣膜修复,52例(34%)行瓣膜置换;采用早期手术、彻底切除感染组织、宽松使用人工材料及补片修复技术的结构化策略,并在术中评估修复耐久性。
  • 采用landmark分析评估瓣膜修复对总生存的影响。

主要发现

  • 院内死亡率为15.4%(修复14例 vs 置换9例,P=0.642)。
  • 无残留感染性心内膜炎病例或早期再手术。
  • Cox比例风险分析显示,术后1年内瓣膜置换不劣于修复(HR 1.134,95%CI 0.504-2.540,P=0.76)。
  • 术后1年以后,置换与生存率降低相关(HR 2.534,95%CI 1.002-6.406,P=0.049)。
  • 复发感染性心内膜炎的免于复发率(P=0.47)和二尖瓣再干预率(P=0.52)在修复与置换间无差异。

临床怎么用

  • 对原生二尖瓣活动性感染性心内膜炎患者,应在广泛瓣膜破坏前尽早手术,以增加耐久修复的可能性。
  • 术中应彻底切除感染组织、宽松使用人工材料及补片技术,并对预期修复耐久性进行严格评估,耐久性存疑时不行修复。

局限性

  • 单中心回顾性设计,样本量有限(149例),可能存在选择偏倚。
  • 修复组与置换组基线特征未在摘要中报告,组间比较可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mitral valve repair in native active infective endocarditis is technically challenging. The survival benefit over valve replacement is poorly established and possibly absent because of the high risk of repair failure and reoperation. In this study, we explore the results of our structured approach in these patients. METHODS: Between January 2000 and January 2017, 149 patients underwent surgery for native mitral infective endocarditis. Among them, 97 (66%) patients underwent valve repair and 52 (34%) underwent valve replacement. Our structured approach consisted of early surgery, radical resection of infected tissue, liberal use of prosthetic materials and 'patch' repair techniques. A critical assessment of expected repair durability was made intraoperatively and repair was not performed if concerns of long-term durability existed. To study the effects of valve repair on overall survival, landmark analysis was performed. RESULTS: In-hospital mortality was 15.4% (14 repair vs 9 replacement patients; P = 0.642). There were no residual infective endocarditis cases or early reoperations. On Cox proportional hazards analysis, valve replacement was not inferior to repair within 1-year post-surgery [hazard ratio (HR) 1.134, 95% confidence interval (CI) 0.504-2.540; P = 0.76]. Beyond 1 year post-surgery, replacement was associated with decreased survival (HR 2.534, 95% CI 1.002-6.406; P = 0.049). There were no differences in freedom from recurrent infective endocarditis (P = 0.47) and mitral valve reintervention (P = 0.52). CONCLUSIONS: Active mitral valve endocarditis remains a complex disease with significant early and late morbidity and mortality. A structured approach allows valve repair in two-thirds of patients. Clinical results could be improved by focussing on early surgery, prior to extensive valve destruction, to enable durable repairs and improve late outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Defauw RJ, Tomšič A, van Brakel TJ, et al. A structured approach to native mitral valve infective endocarditis: Is repair better than replacement? Eur J Cardiothorac Surg. 2020. PMID: 32333009. doi:10.1093/ejcts/ezaa079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。